Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

When are results of single-arm studies dramatic?

Single-arm phase II trials can provide compelling results that facilitate the approval of a new therapy. Designing and interpreting single-arm studies based on four principles — instinct, comparative analysis, statistical soundness and like-for-like comparisons — can provide indications as to which drugs are most likely to provide improved therapeutic options for patients.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Tang, H. et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J. Clin. Oncol. 28, 1936–1941 (2010).

    Article  Google Scholar 

  2. 2.

    Zia, M. I., Siu, L. L., Pond, G. R. & Chen, E. X. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J. Clin. Oncol. 23, 6982–6991 (2005).

    CAS  Article  Google Scholar 

  3. 3.

    Seymour, L. et al. The design of Phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin. Cancer Res. 16, 1764–69 (2010).

    CAS  Article  Google Scholar 

  4. 4.

    Lara, P. N. & Redman, M. W. The hazards of randomized phase II trials. Ann. Oncol. 23, 7–9 (2012).

    CAS  Article  Google Scholar 

  5. 5.

    Korn, E. L., Freidlin, B., Abrams, J. S. & Halabi, S. Design issues in randomized phase II/III trials. J. Clin. Oncol. 30, 667–671 (2012).

    CAS  Article  Google Scholar 

  6. 6.

    Monzon, J. G. et al. Correlation of single arm versus randomized Phase 2 oncology trial characteristics with phase 3 outcome. Eur. J. Cancer 51, 2501–2507 (2015).

    Article  Google Scholar 

  7. 7.

    Joseph, A. How well can you predict the outcome of clinical trials? Not as well as you think (2018).

  8. 8.

    Necchi, A. et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Eur. Urol. 71, 281–289 (2017).

    CAS  Article  Google Scholar 

  9. 9.

    Chen, Y., Chen, Z. & Mori, M. A new statistical decision rule for single arm Phase II clinical oncology trials. Stat. Methods Med. Res. 25, 118–132 (2016).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Marc J. Kahn.

Ethics declarations

Competing interests

R.H.G. is an employee of Credit Suisse Securities. The other authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Glassman, R.H., Kim, G. & Kahn, M.J. When are results of single-arm studies dramatic?. Nat Rev Clin Oncol 17, 651–652 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing